AI Article Synopsis
- Clear cell carcinoma is the most prevalent type of renal cell carcinoma, often showing poor response to conventional treatments and leading to a grim outlook for patients.
- New systemic agents have enhanced treatment outcomes, and their combination with radiation therapy may offer new options for patient care.
- A case study is presented where a patient experienced significant improvement after low-dose palliative radiation therapy, even after failing targeted and immunotherapy treatments.
Article Abstract
Clear cell carcinoma is the most common form of renal cell carcinoma (RCC). Metastatic RCC is poorly responsive to treatment and has a bleak prognosis. Newer systemic agents have improved outcomes. Furthermore, their interaction with radiation treatment (RT) may provide further therapeutic options. RCC is considered to be radioresistant, however we report the case of a patient with progression on targeted therapy and immunotherapy who achieved a substantial and sustained local, and possibly abscopal, response to low dose palliative radiation therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323401 | PMC |
| http://dx.doi.org/10.1159/000493913 | DOI Listing |
Publication Analysis
Top Keywords
renal cell
8
palliative radiation
8
radiation treatment
8
substantial sustained
8
cell carcinoma
8
advanced renal
4
cell cancer
4
cancer low-dose
4
low-dose palliative
4
treatment
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!